Marek Tomala
Jagiellonian University Medical College
32 Papers
203 Citations
Marek Tomala is an academic researcher from Jagiellonian University Medical College. The author has contributed to research in topics: Myocardial infarction & Percutaneous coronary intervention. The author has an hindex of 10, co-authored 32 publications. Previous affiliations of Marek Tomala include Jagiellonian University.
Chat about Author
Papers
Extent of RV dysfunction and myocardial infarction assessed by CMR are independent outcome predictors early after STEMI treated with primary angioplasty.
Tomasz Miszalski-Jamka,Piotr Klimeczek,Marek Tomala,Maciej Krupiński,George M. Zawadowski,Jessica Noelting,Michal J. Lada,Katarzyna Sip,Robert Banyś,Wojciech Mazur,Dean J. Kereiakes,Krzysztof Żmudka,Mieczysław Pasowicz +12 more
TL;DR: The extent of RVMI and RV dysfunction assessed early after STEMI are independent outcome predictors, which provide incremental prognostic value to clinical data, LV systolic function, and infarct burden.
65
Incidence of Postoperative Delirium and Its Impact on Outcomes After Transcatheter Aortic Valve Implantation
Maciej Bagienski,Paweł Kleczyński,Artur Dziewierz,Lukasz Rzeszutko,Danuta Sorysz,Jarosław Trębacz,Robert Sobczyński,Marek Tomala,Maciej Stapor,Dariusz Dudek +9 more
TL;DR: The occurrence of delirium after TAVI may help to identify patients with worse short- and long-term outcomes, and be a source of inspiration for identifying patients with bad short-and-long-term clinical outcomes.
46
Short- and intermediate-term improvement of patient quality of life after transcatheter aortic valve implantation: a single-centre study.
Paweł Kleczyński,Maciej Bagienski,Danuta Sorysz,Łukasz Rzeszutko,Jarosław Trębacz,Marek Tomala,Robert Sobczyński,Artur Dziewierz,Andrzej Surdacki,Dariusz Dudek +9 more
TL;DR: TAVI provides improved quality of life (QoL) and effectively relieves symptoms and comparison of baseline values with follow-up data at one, six and 12 months after TAVI showed significant improvement of QoL.
Urinary 11‐Dehydro‐Thromboxane B2 as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study
Wojciech Szczeklik,Edyta Stodółkiewicz,Marcin Rzeszutko,Marek Tomala,Anton Chrustowicz,Krzysztof Żmudka,Marek Sanak +6 more
TL;DR: 11‐dehydro‐TXB 2 predicts 1‐year cumulative MACEs in AMI patients and provides prognostic information on the left ventricular performance and 3 other variables (diabetes, multivessel disease, andleft ventricular ejection fraction) were found to be best 1‐ year cumulative Mace predictors.
26
Early- and mid-term outcomes after transcatheter aortic valve implantation. Data from a single-center registry.
Maciej Bagienski,Paweł Kleczyński,Artur Dziewierz,Lukasz Rzeszutko,Danuta Sorysz,Jarosław Trębacz,Robert Sobczyński,Marek Tomala,Maciej Stapor,Andrzej Gackowski,Dariusz Dudek +10 more
TL;DR: A mortality rate of < 20% after 12 months seems acceptable given the high-risk population enrolled, and TAVI improves survival and quality of life as compared to medical treatment in inoperable patients.